Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Hershey

Microsoft

Do you think I'd be writing for InvestorPlace if I knew the three top stocks to invest in right now? Of course not.

3 Top Stocks to Invest In Right Now

Merck MRK, -0.46% and privately held Orna Therapeutics said Tuesday they have agreed to collaborate to discover and develop programs, including vaccines and therapeutics, in the fields of infectious disease and oncology. Under the terms of the deal, Merck will make an upfront payment of $150 million, to be expensed in the third quarter and included in non-GAAP results.

Merck and Orna Therapeutics to collaborate in deal entitling Orna to up to $3.5 billion in milestone payments

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Accepts Submission of sNDA for LYNPARZA® in Combination With Abiraterone and Prednisone for Patients With mCRPC and Grants Priority Review

FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck and Orna Therapeutics Collaborate to Advance Orna's Next Generation of RNA Technology

Merck and Orna Therapeutics Collaborate to Advance Orna's Next Generation of RNA Technology

Seagen

Seagen lost a royalty battle Friday, but SGEN stock jumped on the potential the rumored Merck acquisition could be looming. The post Does Merck Finally Have The Fodder It Needs To Buy Seagen?

Does Merck Finally Have The Fodder It Needs To Buy Seagen?

Bank of America

Bunge Global SA

Freeport-McMoRan

NRG Energy

Phillips 66

After a dreadful first six months of 2022, which culminated with a S&P 500 market low of 3,666 on June 16, we have seen one of the strongest rallies in a while.

Why You Should Sell the Rally and Buy These 7 Goldman Sachs Conviction List Dividend Blue Chips

AbbVie

AmerisourceBergen

Bristol-Myers

Quest Diagnostics

HCA Healthcare

Labcorp Holdings Inc

McKesson

Pfizer

Viatris

The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.

10 defensive stocks that can also provide you with growth and dividends over the long term

Amgen

Chemocentryx

Global Blood Therapeutics

SPDR S&P Pharmaceuticals ETF

Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.

Get ready for more merger mania in pharma sector the rest of the year

American Electric Power Company

Chevron

Southern Company

Exxon Mobil

We have narrowed our search to five U.S. corporate giants. These are; XOM, CVX, AEP, MRK and SO.

5 High-Flying U.S. Corporate Giants to Buy Despite Volatility

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.

3 Pharma Stocks' Post-Earnings Price Moves

Germany's Merck KGaA saw adjusted earnings rise 13.1% in the second quarter as higher revenues from its biotech lab equipment and its chemicals for semiconductor production were further bolstered by a strong U.S. dollar.

Merck KGaA's adjusted earnings boosted by strong dollar

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)--Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA Plus LENVIMA Versus LENVIMA Monotherapy in uHCC

Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA Plus Chemotherapy in Patients With mCRPC

Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Big pharma executives are worried that one part of the Inflation Reduction Act will reduce their companies' profits.

Medicare Drug Pricing Changes Could Be Coming: Time to Ditch Pharma Stocks?

Merck has an outstanding oncology portfolio that will drive growth in the foreseeable future. Strong fundamentals and cash position ensure Merck's growth will be well supported.

Merck: Strong Oncology Pipeline

Biogen

BioMarin Pharmaceutical

Medpace Holdings

Thermo Fisher Scientific

Zimmer Biomet Hlds

You're tempted to increase exposure to stocks because of the market's strength. But you're still gun shy because of the painful selloff.

These eight health-care stocks can keep you invested in the market with less worry

Comcast

Prologis

Simon Property Group

Taiwan Semiconductor Manufacturing

The five stocks I picked at the beginning of the year collectively outperformed the S&P 500 by roughly 10%, excluding dividends. On average, my five picks for the latter half of the year have bigger yields and higher 5-year dividend growth rates.

My Top 5 Dividend Stocks For The 2nd Half Of 2022 (My First 5 Picks Beat The S&P By 10%)

Merck (MRK) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Looking for a Growth Stock? 3 Reasons Why Merck (MRK) is a Solid Choice

Merck (MRK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Merck (MRK) Upgraded to Buy: Here's What You Should Know

Both Merck and AbbVie reported their Q2 earnings last week, and this article provides a review of their earnings. We like both given their strong pipeline and safe dividends.

Merck And AbbVie Q2: Pipeline And Dividends In Focus

American Express

Kraft Heinz

Coca-Cola

Kroger

Verizon

If any investor has stood the test of time, it's Warren Buffett, and with good reason.

7 Warren Buffett Dividend Stocks That Every Total Return Investor Should Own

Merck (MRK) beats on Q2 estimates for earnings and sales. The company continues to see robust growth in COVID drug sales and Keytruda and Gardasil sales.

Merck (MRK) Q2 Earnings & Revenues Top, COVID Drug Helps Sales

Merck & Co, Inc. (NYSE:MRK ) Q2 2022 Earnings Conference Call July 28, 2022 8:00 AM ET Company Participants Peter Dannenbaum - VP, IR Robert Davis - President, CEO & Director Caroline Litchfield - EVP & CFO Dean Li - EVP & President;, Merck Research Laboratories Conference Call Participants Evan Seigerman - BMO Capital Markets Andrew Baum - Citigroup Louise Chen - Cantor Fitzgerald & Co. Carter Gould - Barclays Bank Seamus Fernandez - Guggenheim Securities Geoffrey Meacham - Bank of America Merrill Lynch Umer Raffat - Evercore ISI Mara Goldstein - Mizuho Securities Operator Ladies and gentlemen, thank you for standing by. Good morning.

Merck & Co, Inc. (MRK) CEO Robert Davis on Q2 2022 Results - Earnings Call Transcript

Merck (MRK) delivered earnings and revenue surprises of 11.98% and 5.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Merck Stock (MRK)